Social Media Ideas for Mnkd

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million

This disposition was tied to vesting of performance-based RSUs at 83% of the target.

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk

Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Ind...

What This MannKind Filing Reveals About Three Years of Underperformance

Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million.

Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?

Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company.

Novo Nordisk: The Oral Wegovy Promise

Management

Management Anonymous (not verified) Mon, 06/29/2026 - 03:04 field_thread_url https://cafepharma.com/boards/threads/management.710052/ bo...

Management

Management Anonymous (not verified) Sun, 07/05/2026 - 06:08 field_thread_url https://cafepharma.com/boards/threads/management.710052/ bo...

Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M deal

Dimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk

Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company.

Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail

A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the...

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win

Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes b...

Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline

Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs

Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this...

Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal with Californian medtech Vivani Medical to help.

CMCS realignment

CMCS realignment Anonymous (not verified) Sun, 08/09/2026 - 00:30 field_thread_url https://cafepharma.com/boards/threads/cmcs-realignment.717922/...

<![CDATA[Novartis to Acquire Myricx Bio for $1.1 Billion]]>

CMCS realignment

CMCS realignment Anonymous (not verified) Wed, 08/19/2026 - 06:37 field_thread_url https://cafepharma.com/boards/threads/cmcs-realignment.717922/...

DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

<![CDATA[FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults ]]>